You are here
Interview with Dr. Susanne A. Wolf, Max-Delbrück-Center in the Helmholtz Association. Berlin, GermanyThe importance of the microglia has gained a lot of attention recently, as a novel therapeutic target in psychiatric disorders...
Interview with Dr. Maarten Titulaer, recorded at ECNP Congress 2016, ViennaDiscovered in 2007, anti-NMDA receptor encephalitis is a disorder that features a lot of psychiatric symptoms – patients become psychotic,...
Neurogenesis and neurotoxicity: Pt 2 of roundtable with Dr Henry Nasrallah, Dr Jim van Os, and Dr Diana Perkins at ECNP 2014.In part 2 of this round table, the group suggest that a better understanding of neurogenesis could open up novel...
Decreased interleukin-10 serum levels in first-episode drug-naïve schizophrenia: Relationship to psychopathology
Mei Hong Xiu, Gui Gang Yang, Yun Long Tan, Da Chun Chen, Shu Ping Tan, Zhi Ren Wang, Fu De Yang, Olaoluwa Okusaga, Jair C. Soares, Xiang Yang Zhang
Schizophrenia Research, Volume 156, Issue 1, June 2014, Pages 9–14
Jakub Tomasik, Hassan Rahmoune, Paul C. Guest, Sabine Bahn
Schizophrenia Research, In Press, Corrected Proof
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism
Brenda Vincenzi, Shannon Stock, Christina P.C. Borba, Sarah M. Cleary, Claire E. Oppenheim, Liana J. Petruzzi, Xiaoduo Fan, Paul M. Copeland, Oliver Freudenreich, Corinne Cather, David C. Henderson
Schizophrenia Research, Volume 159, Issues 2–3, November 2014, Pages 395–403
Celso Arango Discusses a New Meta-analysis Presented at ECNP, which Indicates Anti-inflammatory Medicines Potentially Improve the Efficacy of Existing Treatments.Dr Arango discusses a Meta-analysis study which shows that anti-inflammatory drugs can potentially benefit patients with schizophrenia, in combination with...